Skip to main content

Table 1 Patient characteristics, tumor characteristics, therapy regimen, chemotherapy and radiotherapy characteristics

From: Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

Patient characteristics

 Sex

  Men

81

  Women

53

 Age [y]

  Median

67.5

  Min

21

  Max

87

 Weight [kg]

  Median

80

  Min

45

  Max

140

 Height [m]

  Median

1.71

  Min

1.51

  Max

1.93

 BMI [kg/m2]

  Median

27.34

  Min

17.58

  Max

43.82

Therapy regimen

 Clinical trials

  CAO/ARO/AIO-04

111

  TransValid-KFO179/GRCSG-A

15

  TransValid-KFO179/GRCSG-B

8

 Therapy sequence

  RCT-TME-CT

126

  RCT-CT-TME

8

CT characteristics

 CT regimen

  5-FU-mono

78

  FOLFOX

56

 5-FU plasma levels (AUC [mg∙h/l])

  Median

20.37

  Min

2.02

  Max

100.00

RT characteristics

 RT technique

 

  3DCRT

87

  IMRT

2

  VMAT

31

  3DCRT and VMAT

14

PTV size [cm3]

  Median

1414.7

  Min

998.6

  Max

2735.5

  1. RCT radiochemotherapy, TME total mesorectal excision, CT chemotherapy, RT radiotherapy, 5-FU 5-fluorouracil, FOLFOX 5-FU and oxaliplatin, 3DCRT 3D-conformal radiotherapy, IMRT intensity modulated radiotherapy, VMAT volumetric modulated arc therapy, AUC area under the concentration-time curve, PTV size planning target volume size